Publication:
The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Simple item page
dc.contributor.authorTamma, Pranita D
dc.contributor.authorRodriguez-Bano, Jesus
dc.date.accessioned2023-01-25T09:44:33Z
dc.date.available2023-01-25T09:44:33Z
dc.date.issued2017-04-01
dc.description.abstractThe continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.
dc.description.versionSi
dc.identifier.citationTamma PD, Rodriguez-Bano J. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections. Clin Infect Dis. 2017 Apr 1;64(7):972-980.
dc.identifier.doi10.1093/cid/cix034
dc.identifier.essn1537-6591
dc.identifier.pmcPMC5848369
dc.identifier.pmid28362938
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848369/pdf
dc.identifier.unpaywallURLhttps://academic.oup.com/cid/article-pdf/64/7/972/24254903/cix034.pdf
dc.identifier.urihttp://hdl.handle.net/10668/11031
dc.issue.number7
dc.journal.titleClinical infectious diseases : an official publication of the Infectious Diseases Society of America
dc.journal.titleabbreviationClin Infect Dis
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen Macarena
dc.page.number972-980
dc.provenanceRealizada la curación de contenido 24/07/2025.
dc.publisherOxford University Press
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.relation.publisherversionhttps://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cix034
dc.rights.accessRightsRestricted Access
dc.subjectESBLs
dc.subjectcarbapenems
dc.subjectcefepime
dc.subjectcephamycins
dc.subjectpiperacillin-tazobactam.
dc.subject.decsBeta‑lactamasas de espectro extendido
dc.subject.decsEnterobacterales
dc.subject.decsCarbapenémicos
dc.subject.decsPiperacilina‑tazobactam
dc.subject.decsCeftazidima‑avibactam
dc.subject.decsCeftolozano‑tazobactam
dc.subject.meshAnti-Bacterial Agents
dc.subject.meshCefepime
dc.subject.meshCephalosporins
dc.subject.meshCephamycins
dc.subject.meshEnterobacteriaceae
dc.subject.meshEnterobacteriaceae Infections
dc.subject.meshHumans
dc.subject.meshMicrobial Sensitivity Tests
dc.subject.meshPenicillanic Acid
dc.subject.meshPiperacillin
dc.subject.meshPiperacillin, Tazobactam Drug Combination
dc.subject.meshTreatment Outcome
dc.subject.meshbeta-Lactam Resistance
dc.subject.meshbeta-Lactamase Inhibitors
dc.subject.meshbeta-Lactamases
dc.titleThe Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number64
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format
Download

Collections

Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía